A first human study of A2AR antagonists for cancer treatment has confirmed that combined A2AR antagonists and Anti-PD-L1 has anti-tumor activity in patients with refractory renal cell carcinoma, correlating with increased tumor infiltration of CD8+ T cells (Fong et al., 2020). The gene discussed is CD8A; the disease is cancer.